| Company | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
|---|---|---|---|---|---|---|---|
| Vyome Holdings, Inc | Chief Financial Officer | Common Stock | 762 | $2,438 | $3.20 | 15 Aug 2025 | Direct |
| AngioGenex, Inc. | Director, INDEPENDENT DIRECTOR | Stock Option | 850,000 | 02 Sep 2021 | Direct |
| Symbol | Company | Period | Transactions | Value $ | Form Type | Role | Filing Time |
|---|---|---|---|---|---|---|---|
| RSLS | Vyome Holdings, Inc | 15 Aug 2025 | 1 | $0 | 4 | Chief Financial Officer | 11 Sep 2025, 21:21 |
| RSLS | Vyome Holdings, Inc | 15 Aug 2025 | 0 | $0 | 3 | Chief Financial Officer | 11 Sep 2025, 21:20 |
| /report/000095017023043314-dickey-robert-iv-2023-08-14 | Invitae Corp | 14 Aug 2023 | 0 | $0 | 3 | Interim Chief Financial Officer Exhibit List: Exhibit 24 - Power of Attorney | 17 Aug 2023, 19:40 |
| ENVB | Enveric Biosciences, Inc. | 09 Sep 2022 | 0 | $0 | 3 | Chief Financial Officer | 23 Sep 2022, 14:43 |
| AIMI | AIM ImmunoTech Inc. | 04 Apr 2022 | 0 | $0 | 3 | Chief Financial Officer | 04 Apr 2022, 18:43 |
| /report/000146970922000011-dickey-robert-iv-2021-12-31 | AngioGenex, Inc. | 31 Dec 2021 | 1 | +$32,500 | 5 | Director, INDEPENDENT DIRECTOR | 16 Feb 2022, 12:49 |